A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
Author(s) -
Sandra Andorf,
Natasha Purington,
Divya Kumar,
Andrew Long,
Katherine O'Laughlin,
Scott H. Sicherer,
Hugh A. Sampson,
Antonella Cianferoni,
Terri Brown Whitehorn,
Daniel Petroni,
Melanie Makhija,
Rachel G. Robison,
Michelle B. Lierl,
Stephanie Logsdon,
Manisha Desai,
Stephen J. Galli,
Efren Rael,
Amal Assa’ad,
R. Sharon Chinthrajah,
Jacqueline A. Pongracic,
Jonathan M. Spergel,
Jonathan S. Tam,
Stephen A. Tilles,
Julie Wang,
Kari C. Nadeau
Publication year - 2019
Publication title -
eclinicalmedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.915
H-Index - 20
ISSN - 2589-5370
DOI - 10.1016/j.eclinm.2018.12.006
Subject(s) - medicine , discontinuation , desensitization (medicine) , dosing , omalizumab , placebo , randomized controlled trial , food allergy , oral food challenge , allergy , immunology , immunoglobulin e , alternative medicine , receptor , pathology , antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom